Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy.
Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
Biochem Pharmacol. 2022 Jan;195:114811. doi: 10.1016/j.bcp.2021.114811. Epub 2021 Oct 18.
It is well known that cancer is an aggressive disease, often associated with relapse, in many cases due to drug resistance. Cancer stem cell and clonal evolution are frequently causes of innate or acquired drug resistance. Current RNA sequencing technologies do not distinguish gene expression of different cell lineages because they are based on bulk cell studies. Single-cell RNA sequencing technologies and related bioinformatics clustering and differential expression analysis represent a turning point in cancer research. They are emerging as essential tools for dissecting tumors at single-cell resolution and represent novel tools to understand carcinogenesis and drug response. In this review, we will outline the role of these new technologies in addressing cancer heterogeneity and cell lineage-dependent drug resistance.
众所周知,癌症是一种侵袭性疾病,常伴有复发,在许多情况下是由于耐药性所致。癌症干细胞和克隆进化是导致先天或获得性耐药的常见原因。目前的 RNA 测序技术无法区分不同细胞谱系的基因表达,因为它们基于批量细胞研究。单细胞 RNA 测序技术和相关的生物信息学聚类和差异表达分析代表了癌症研究的一个转折点。它们正在成为解析肿瘤单细胞分辨率的重要工具,并代表了理解癌症发生和药物反应的新工具。在这篇综述中,我们将概述这些新技术在解决癌症异质性和细胞谱系依赖性耐药方面的作用。